Llwytho...
Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study
Tenapanor (RDX5791/AZD1722) is a minimally systemic small‐molecule inhibitor of the sodium/hydrogen exchanger NHE3. Tenapanor acts in the gut to reduce absorption of sodium and phosphate. This phase 1 open‐label, 3‐way crossover study (NCT02226783) evaluated the effect of food on the pharmacodynamic...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Clin Pharmacol Drug Dev |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
John Wiley and Sons Inc.
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5599956/ https://ncbi.nlm.nih.gov/pubmed/28339149 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.341 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|